Bariatric surgery and obesity medicines are options that can complement one another. When deciding, it is useful to compare your clinical situation, the expected benefits, the risks and the follow-up each treatment requires. Neither guarantees a permanent result for everyone.
What are GLP-1 agonists and dual GIP/GLP-1 treatment?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on both GIP and GLP-1 receptors: it is not exactly the same class of medicine. Both influence appetite and fullness, but their indications, doses and precautions are not interchangeable.
The EMA lists weight-management indications in the product information for Wegovy (semaglutide) and Mounjaro (tirzepatide). Choosing a treatment requires a prescription and medical assessment. Not all brands or formulations of an active ingredient are authorised for the same uses. If you are planning a pregnancy or an operation, tell the team about all your medication: precautions are adapted to the medicine and your clinical situation.
What happens when medication is stopped?
Obesity is a chronic disease, and treatment may need to continue. When these medicines are withdrawn, some of the weight lost may be regained. This does not mean addiction: it reflects, among other factors, the persistence of mechanisms that contribute to obesity. Responses vary, and stopping treatment should be accompanied by a follow-up plan.
What does bariatric surgery offer?
Sleeve gastrectomy and gastric bypass change digestive anatomy and metabolic signals. They can achieve substantial weight loss and improve associated conditions, including type 2 diabetes. Diabetes remission is not the same as a guaranteed cure and requires subsequent monitoring.
Surgery also has perioperative and long-term risks. It requires reviews, blood tests and supplements according to the procedure. Weight regain is possible, and some patients need medication or further operations. It should not be presented as a one-off cost or a way to dispense with treatment for ever.
Bariatric surgery and medicines: how to compare them
| Aspect | Medicines | Bariatric surgery |
|---|---|---|
| Choice | Depends on the authorised indications, associated conditions, tolerance and preferences. | Depends on clinical assessment, eligibility criteria, the procedure and surgical risk. |
| Duration | May require prolonged treatment; effectiveness and tolerance are reviewed. | Anatomical changes persist, but follow-up continues in the long term. |
| Risks | Adverse effects and contraindications specific to each medicine. | Surgical, digestive and nutritional risks specific to each operation. |
| Results | Vary according to the medicine, dose, duration and person. | Vary according to the procedure, starting circumstances, duration and person. |
| Costs | The current price and conditions of coverage must be confirmed. | The operation, reviews, supplements and possible subsequent treatments should be included. |
When reading studies, do not directly compare percentage total weight loss with percentage excess weight loss. The population, follow-up period and treatment studied should also match, or their differences should be explained. Universal superiority cannot be inferred from percentages in different trials.
When is each option considered?
Medicines can be used as obesity treatment in their own right, within a comprehensive plan; their role is not limited to preparing for an operation. In some patients, they are combined with surgery before or after the procedure.
The 2022 ASMBS/IFSO recommendations include surgery for a BMI of 35 kg/m² or above, even without comorbidities, and for type 2 diabetes with a BMI of 30 or above. Between 30 and 34.9, surgery may be considered if non-surgical treatment does not achieve sufficient, lasting improvement. Meeting a criterion does not replace individual assessment or imply automatic coverage.
Bariatric surgery assessment in Valencia
At a consultation with Dr. Pablo Aragó Chofre, you can review the treatments you have tried, changes in your weight, associated health conditions and your questions. The aim is to decide with you whether an operation is appropriate or whether other options should be continued or adjusted.
Request an assessment in Valencia. Bring any available blood test results and a list of your current medication; do not stop any treatment on your own.
Medical sources
EMA: Wegovy · EMA: Mounjaro · ASMBS: indications for metabolic and bariatric surgery.
Medical review of the Spanish source: Dr. Pablo Aragó Chofre, specialist in General and Digestive Surgery. Spanish source review date: 11 November 2026. General information for patients; assessment and indications are individualised during consultation.

